Kimia Farma (Persero) Tbk PT operates in the Medicinals and botanicals sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Kimia Farma (Persero) Tbk PT with three other
pharmaceutical manufacturers in Asia:
Tianjin Chase Sun Pharmaceutical Company Limited
sales of 4.22 billion Chinese Renmimbi [US$604.53 million]
of which 51%
Zhejiang Jianfeng Group Company Limited
(3.36 billion Chinese Renmimbi [US$481.20 million]
of which 48%
was Cement/Construction Materials), and
Shanxi Zhendong Pharmaceutical Co Ltd
based in China
(3.42 billion Chinese Renmimbi [US$489.43 million]
of which 109%
was Medicine Manufacture and Sale).
Kimia Farma (Persero) Tbk PT reported sales of 7.45 trillion Indonesian Rupiahs (US$544.90 million)
December of 2018.
increase of 21.7%
versus 2017, when the company's sales were 6.13 trillion Indonesian Rupiahs.
Sales at Kimia Farma (Persero) Tbk PT have increased during each of the previous five years
(and since 2013, sales have increased a total of 71%).
Sales of Retail saw an increase
26.0% in 2018, from
3.27 trillion Indonesian Rupiahs to 4.13 trillion Indonesian Rupiahs.
Not all segments of Kimia Farma (Persero) Tbk PT experienced an increase in sales in 2018:
sales of Manufacturing fell 16.0% to 272.12 billion Indonesian Rupiahs.